Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: New strategies for such patients?

Infection

Volumn 40, Issue 2, 2012, Pages 173-179

  Milan, M ^a   Boninsegna, S ^a   Scribano, L ^a   Lobello, S ^b   Fagiuoli, S ^c   Fabris, P ^d   Buda, A ^a   Martines, D ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b S ANTONIO HOSPITAL   (Italy)

^c Bergamo Hospital   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

Author keywords

HCV; Predictors; Relapse; Viral kinetics

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATTY LIVER; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PREDICTION; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 84862540334     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-011-0219-0     Document Type: Article

References (23)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558-67. (Pubitemid 41196755)
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65. (Pubitemid 32913521)
4. Zeuzem S, Hultcrantz R, Bourlìere M, et al. Peginterferon a-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 and 3. J Hepatol. 2004;40:993-9. (Pubitemid 38670134)
5. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon a-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357:124-34. (Pubitemid 47057730)
6. Mangia A, Santoro R, Minerva N, et al. Peginterferon a-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609-17. (Pubitemid 41007847)
7. Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology. 2009;49:358-63.
8. von Wagner M, Huber M, Berg T, et al. Peginterferon-a-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129: 522-7. (Pubitemid 41096640)
9. Aghemo A, Rumi MG, Soffredini R, et al. Impaired response to interferon-a2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther. 2006;11:797-802. (Pubitemid 44497175)
10. Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon a-2a and ribavirin. Hepatology. 2008;48:1033-43.
11. Sánchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-a2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451-60. (Pubitemid 44142452)
12. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon a-2a (40 KD)/ribavirin. J Hepatol. 2005;43: 425-33. (Pubitemid 41111423)
13. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
14. Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351-8. (Pubitemid 36667315)
15. Dixit NM, Layden-Almer JE, Layden TJ, et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922-4. (Pubitemid 40037156)
16. Hofmann WP, Herrmann E, Sarrazin C, et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 2008;28:1332-43.
17. Rodríguez-Iñigo E, López-Alcorocho JM, Bartolomé J, et al. Percentage of hepatitis C virus-infected hepatocytes is a better predictor of response than serum viremia levels. J Mol Diagn. 2005;7:535-43. (Pubitemid 41479720)
18. Dahari H, Layden-Almer JE, Kallwitz E, et al. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology. 2009; 136:1402-9.
19. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon a-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-52. (Pubitemid 37052151)
20. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon a 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C Virus. J Infect Dis. 2004;189:964-70. (Pubitemid 38373087)
21. Berg T, Von Wagner M, Hinrichsen H, et al. Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon a-2a plus ribavirin in patients with genotype 1 infection up to 72 weeks. Hepatology. 2004;40:238A.
22. Kozielewicz D, Dybowska D, Halota W, et al. Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011;39:433-7.
23. Buti M, Valdés A, Sánchez-Avila F, et al. Extending combination therapy with peginterferon a-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology. 2003;37:1226-7. (Pubitemid 36538703)